Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-B Davion

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Revue Neurologique|July 13, 2021
Electro-clinical presentation of hereditary transthyretin related amyloidosis when presenting as a polyneuropathy of unknown origin in northern FranceJ-B Davion, P Bocquillon, F Cassim, et al.
Revue Neurologique|June 1, 2025
French guidelines for the diagnosis and management of pure hereditary spastic paraplegiaL Mania-Pâris, C Ewenczyk, G Nicolas, et al.
Neuromuscular Disorders : NMD|March 7, 2023
A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapyR Barrois, C Barnerias, E Deladrière, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Revue Neurologique|July 13, 2021
Electro-clinical presentation of hereditary transthyretin related amyloidosis when presenting as a polyneuropathy of unknown origin in northern FranceJ-B Davion, P Bocquillon, F Cassim, et al.
Revue Neurologique|June 1, 2025
French guidelines for the diagnosis and management of pure hereditary spastic paraplegiaL Mania-Pâris, C Ewenczyk, G Nicolas, et al.
Neuromuscular Disorders : NMD|March 7, 2023
A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapyR Barrois, C Barnerias, E Deladrière, et al.
Pageof 2